Mostaghni A A, Hashemi S A, Heydari S T
Division of Gastroenterology and Hepatology, Shiraz University of Medical Sciences, Shiraz, Iran.
Iran Red Crescent Med J. 2011 Jul;13(7):458-63. Epub 2011 Jul 1.
Proton pump inhibitors (PPIs) decrease the rate of rebleeding following endoscopic hemostatic therapy in patients with bleeding peptic ulcers. This study compares the efficacy of oral omeprazole vs intravenous pantoprazole in decrease of rebleeding of peptic ulcer patients.
One hundred and six patients with high risk peptic ulcer were randomized to receive either oral omeprazole (80 mg BID for 3 days) or IV pantoprazole (80 mg bolus and 8 mg/hour infusion for 3 days) followed by omeprazole (20 mg each day for 30 days). All patients underwent upper endoscopy and endoscopic therapy within 24 hours.
Seventeen patients were excluded from the study. Forty four patients were randomly allocated into omeprazole group and 41 patients to IV pantoprazole group. Both groups were similar for factors affecting the outcome. Bleeding reoccurred in five patients of omeprazole group and four patients in pantoprazole group (11.4% vs 9.8 %). The mean hospital stay and blood transfusion were not different in both groups.
Oral omeprazole and IV pantoprazole had equal effects on prevention of rebleeding after endoscopic therapy in patients with high risk bleeding peptic ulcers.
质子泵抑制剂（PPIs）可降低消化性溃疡出血患者内镜止血治疗后的再出血率。本研究比较口服奥美拉唑与静脉注射泮托拉唑在降低消化性溃疡患者再出血方面的疗效。
106例高危消化性溃疡患者被随机分为两组，分别接受口服奥美拉唑（80毫克，每日两次，共3天）或静脉注射泮托拉唑（80毫克推注，8毫克/小时输注，共3天），之后口服奥美拉唑（20毫克，每日一次，共30天）。所有患者均在24小时内接受了上消化道内镜检查及内镜治疗。
17例患者被排除在研究之外。44例患者被随机分配到奥美拉唑组，41例患者被分配到静脉注射泮托拉唑组。两组在影响结果的因素方面相似。奥美拉唑组有5例患者再次出血，泮托拉唑组有4例患者再次出血（11.4%对9.8%）。两组的平均住院时间和输血量无差异。
口服奥美拉唑和静脉注射泮托拉唑在预防高危出血性消化性溃疡患者内镜治疗后再出血方面效果相当。
